User Tools

Site Tools


2005

Since 2005, state-of-the-art therapy in glioblastoma multiforme consists of maximal safe resection followed by combined radiotherapy and chemotherapy with temozolomide, according to Stupp regimen 1). 2) , particularly in patients that demonstrate MGMT promoter methylation. At recurrence there is no consensus as to the standard of care as no therapeutic options have produced substantial survival benefit 3).

1)
Stupp R, Dietrich PY, Ostermann Kraljevic S, et al.. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol. 2002;20(5):1375–1382.
2)
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005 Mar 10;352(10):987-96. PubMed PMID: 15758009.
3)
Weller M, Cloughesy T, Perry JR, Wick W. Standards of care for treatment of recurrent glioblastoma–are we there yet? Neuro Oncol. 2013 Jan;15(1):4-27. doi: 10.1093/neuonc/nos273. Epub 2012 Nov 7. Review. PubMed PMID: 23136223; PubMed Central PMCID: PMC3534423.
2005.txt · Last modified: 2018/08/05 18:45 by administrador